🚀 VC round data is live in beta, check it out!
Cyclopharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cyclopharm and similar public comparables like Chandan Healthcare, Sensus Healthcare, Klea, Bioporto and more.
Cyclopharm Overview
About Cyclopharm
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
Founded
2005
HQ
Employees
95
Website
Financials (LTM)
EV
$67M
Cyclopharm Financials
Cyclopharm reported last 12-month revenue of $23M.
In the same LTM period, Cyclopharm generated had net loss of ($12M).
Revenue (LTM)
Cyclopharm P&L
In the most recent fiscal year, Cyclopharm reported revenue of $19M and EBITDA of ($8M).
Cyclopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $23M | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $12M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 65% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (42%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (53%) | XXX | XXX | XXX |
| Net Profit | ($12M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (52%) | XXX | (48%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cyclopharm Stock Performance
Cyclopharm has current market cap of $70M, and enterprise value of $67M.
Market Cap Evolution
Cyclopharm's stock price is $0.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $67M | $70M | -0.5% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCyclopharm Valuation Multiples
Cyclopharm trades at 2.9x EV/Revenue multiple, and (8.4x) EV/EBITDA.
EV / Revenue (LTM)
Cyclopharm Financial Valuation Multiples
As of March 31, 2026, Cyclopharm has market cap of $70M and EV of $67M.
Equity research analysts estimate Cyclopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cyclopharm has a P/E ratio of (5.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $70M | XXX | $70M | XXX | XXX | XXX |
| EV (current) | $67M | XXX | $67M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (6.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.4x | XXX | XXX | XXX |
| P/E | (5.8x) | XXX | (7.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cyclopharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cyclopharm Margins & Growth Rates
Cyclopharm's revenue in the last fiscal year grew by 21%.
Cyclopharm's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Cyclopharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (42%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 258% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 78% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cyclopharm Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chandan Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Sensus Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Klea | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioporto | XXX | XXX | XXX | XXX | XXX | XXX |
| InspireMD | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cyclopharm M&A Activity
Cyclopharm acquired XXX companies to date.
Last acquisition by Cyclopharm was on XXXXXXXX, XXXXX. Cyclopharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cyclopharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCyclopharm Investment Activity
Cyclopharm invested in XXX companies to date.
Cyclopharm made its latest investment on XXXXXXXX, XXXXX. Cyclopharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cyclopharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cyclopharm
| When was Cyclopharm founded? | Cyclopharm was founded in 2005. |
| Where is Cyclopharm headquartered? | Cyclopharm is headquartered in Australia. |
| How many employees does Cyclopharm have? | As of today, Cyclopharm has over 95 employees. |
| Is Cyclopharm publicly listed? | Yes, Cyclopharm is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Cyclopharm? | Cyclopharm trades under CYC ticker. |
| When did Cyclopharm go public? | Cyclopharm went public in 2007. |
| Who are competitors of Cyclopharm? | Cyclopharm main competitors are Chandan Healthcare, Sensus Healthcare, Klea, Bioporto. |
| What is the current market cap of Cyclopharm? | Cyclopharm's current market cap is $70M. |
| What is the current revenue of Cyclopharm? | Cyclopharm's last 12 months revenue is $23M. |
| What is the current revenue growth of Cyclopharm? | Cyclopharm revenue growth (vs. last FY) is 21%. |
| What is the current EV/Revenue multiple of Cyclopharm? | Current revenue multiple of Cyclopharm is 2.9x. |
| Is Cyclopharm profitable? | No, Cyclopharm is not profitable. |
| What is the current net income of Cyclopharm? | Cyclopharm's last 12 months net income is ($12M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.